Friday, June 24, 2011 1:16:14 PM
YOU MAY HAVE but it's quite clear CGAQ has not. I do not agree
that the price per share is where it is at because we do not have
a signed contract. The PPS is in my opinion where it is at due to
poor press releases that contained exaggerations that were so
obvious my grandson laughed at them. ( RE: 65,000,000 households).
and the dilution of shares by so called investors.
The death of the jockey, which by the way was first reported by me at IHUB
and was scoffed at by some, had nothing to do with the slot parlor that
came at a later time.
I agree with you, when you say the slot question has been overblown.
I am not referring to the slots per se but the credibility or lack of it
that is associated with it.
I realize Roberto can not post things here, just for us. It would be
illegal for him to do so. I am of the opinion that if CGAQ puts out
a press release clarifying their past mistakes, this stock will begin
to go up in value.
There are many pink sheet stocks that have nothing compared to
what CGAQ has, that is selling for a heck of a lot more. One has to
ask themselves, what is the reason why? I firmly believe its credibility.
If I sound like a broken record, it is because I want to see a correction,
so the stock goes up in price.
that the price per share is where it is at because we do not have
a signed contract. The PPS is in my opinion where it is at due to
poor press releases that contained exaggerations that were so
obvious my grandson laughed at them. ( RE: 65,000,000 households).
and the dilution of shares by so called investors.
The death of the jockey, which by the way was first reported by me at IHUB
and was scoffed at by some, had nothing to do with the slot parlor that
came at a later time.
I agree with you, when you say the slot question has been overblown.
I am not referring to the slots per se but the credibility or lack of it
that is associated with it.
I realize Roberto can not post things here, just for us. It would be
illegal for him to do so. I am of the opinion that if CGAQ puts out
a press release clarifying their past mistakes, this stock will begin
to go up in value.
There are many pink sheet stocks that have nothing compared to
what CGAQ has, that is selling for a heck of a lot more. One has to
ask themselves, what is the reason why? I firmly believe its credibility.
If I sound like a broken record, it is because I want to see a correction,
so the stock goes up in price.
Recent BSEM News
- BioStem Technologies to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/31/2026 08:05:00 PM
- BioStem Technologies Announces the Publication of its Audited Financial Statements for Fiscal Years 2024 and 2025 • GlobeNewswire Inc. • 03/30/2026 11:00:00 AM
- BioStem Technologies Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 03/24/2026 08:05:00 PM
- BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair • GlobeNewswire Inc. • 03/23/2026 03:40:56 PM
- BioStem Appoints Jodi Ungrodt to Board of Directors as Audit Committee Chair • GlobeNewswire Inc. • 03/23/2026 11:00:00 AM
- BioStem Technologies to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on March 24, 2026 • GlobeNewswire Inc. • 03/11/2026 08:05:00 PM
- BioStem Technologies to Present at the 46th Annual TD Cowen Healthcare Conference • GlobeNewswire Inc. • 02/20/2026 12:00:00 PM
- BioStem Technologies Highlights Alignment with FDA’s Openness to Bayesian Statistical Approaches in Clinical Research • GlobeNewswire Inc. • 02/03/2026 09:05:00 PM
- BioStem Technologies Advances Entry into the Acute Wound Care Market with Acquisition of BioTissue Holdings’ Surgical and Wound Care Business • GlobeNewswire Inc. • 01/21/2026 10:30:00 PM
- BioStem Technologies Comments on Withdrawal of CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes • GlobeNewswire Inc. • 01/07/2026 09:05:00 PM
- BioStem Technologies Products Placed on “12-Month Status Quo Period” List in Update to CMS CY 2026 Final Medicare Reimbursement Rule for Skin Substitutes • GlobeNewswire Inc. • 12/18/2025 12:00:00 PM
- BioStem Technologies® to Debut American Amnion™ at the 2025 Desert Foot Multi-Disciplinary Limb Salvage and Wound Care Conference • GlobeNewswire Inc. • 12/10/2025 12:00:00 PM
- BioStem Technologies Expands Product Access in Medicaid • GlobeNewswire Inc. • 11/25/2025 01:59:13 PM
- BioStem Technologies Reports Third Quarter 2025 Financial Results • GlobeNewswire Inc. • 11/13/2025 09:02:00 PM
- BioStem Technologies Announces Filing of Restated Financial Statements • GlobeNewswire Inc. • 11/13/2025 09:01:00 PM
- BioStem Technologies Provides Comments on CMS CY 2026 Final Medicare Reimbursement Rule Changes for Skin Substitutes • GlobeNewswire Inc. • 11/05/2025 09:05:00 PM
- BioStem Technologies Secures Land Purchase at the Research Park at Florida Atlantic University in Boca Raton for Future Headquarters • GlobeNewswire Inc. • 11/05/2025 12:00:00 PM
- BioStem Technologies Reports Positive Top-Line Clinical Results Demonstrating Superior Outcomes with BioRetain® Allograft in Diabetic Foot Ulcers • GlobeNewswire Inc. • 10/31/2025 11:00:00 AM
- BioStem Technologies to Host Third Quarter 2025 Financial Results Conference Call on November 13, 2025 • GlobeNewswire Inc. • 10/30/2025 08:05:00 PM
- BioStem Technologies Appoints KPMG as its Independent Registered Public Accountant • GlobeNewswire Inc. • 10/27/2025 08:15:00 PM
- BioStem Technologies Expands Partnership with the Florida Panthers as a Sponsor for the 13th Season of the “Heroes Among Us” Program • GlobeNewswire Inc. • 10/02/2025 04:00:00 PM
